Pegasus Asset Management, Inc. Biomarin Pharmaceutical Inc Transaction History

Pegasus Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$71.48 - $86.85 $1.76 Million - $2.14 Million	-24,675 Closed	0 $0
Q1 2022 Apr 20, 2022	SELL	$74.28 - $92.69 $10,547 - $13,161	-142 Reduced 0.57%	24,675 $1.9 Million
Q4 2021 Jan 18, 2022	BUY	$71.72 - $91.47 $35,931 - $45,826	501 Added 2.06%	24,817 $2.19 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $122,099 - $139,572	1,633 Added 7.2%	24,316 $1.88 Million
Q2 2021 Jul 29, 2021	BUY	$75.51 - $84.79 $28,165 - $31,626	373 Added 1.67%	22,683 $1.89 Million
Q1 2021 Apr 28, 2021	BUY	$74.73 - $90.69 $159,772 - $193,895	2,138 Added 10.6%	22,310 $1.69 Million
Q4 2020 Jan 15, 2021	BUY	$72.61 - $90.2 $23,961 - $29,766	330 Added 1.66%	20,172 $1.77 Million
Q3 2020 Oct 13, 2020	BUY	$71.87 - $131.03 $55,627 - $101,417	774 Added 4.06%	19,842 $1.51 Million
Q2 2020 Aug 11, 2020	SELL	$79.55 - $124.22 $4,375 - $6,832	-55 Reduced 0.29%	19,068 $2.35 Million
Q1 2020 Apr 27, 2020	BUY	$71.37 - $96.85 $15,844 - $21,500	222 Added 1.17%	19,123 $1.62 Million
Q4 2019 Jan 22, 2020	BUY	$64.27 - $86.37 $1.21 Million - $1.63 Million	18,901 New	18,901 $1.6 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Pegasus Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Pegasus Asset Management, Inc. with notifications on news.